Inactive Instrument

GENFIT Stock Euronext Paris

Equities

FR0004163111

Biotechnology & Medical Research

End-of-day quote Euronext Paris
- EUR - Intraday chart for GENFIT
Sales 2024 * 89.63M 95.94M Sales 2025 * 48.78M 52.21M Capitalization 161M 172M
Net income 2024 * 15M 16.05M Net income 2025 * -21M -22.48M EV / Sales 2024 * 1.49 x
Net cash position 2024 * 27.6M 29.54M Net cash position 2025 * 44.9M 48.06M EV / Sales 2025 * 2.38 x
P/E ratio 2024 *
6.88 x
P/E ratio 2025 *
24.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.72%
More Fundamentals * Assessed data
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
Genfit: net loss widens in 2023 CF
Genfit S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
Genfit: 41% sales growth in 2023 CF
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
More news
Managers TitleAgeSince
Chief Executive Officer 56 18-04-30
Founder 68 99-08-31
Director of Finance/CFO 50 21-04-21
Members of the board TitleAgeSince
Director/Board Member 67 21-03-03
Founder 68 99-08-31
Founder 52 99-09-14
More insiders
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
More about the company